Researchers at Novo Nordisk have developed a new glucose-sensitive insulin called NNC2215, designed to reduce the risk of hypoglycemia, a common complication of insulin therapy. NNC2215 adjusts its activity based on blood sugar levels, thanks to specialized components added to the insulin molecule. Early studies showed that NNC2215 responds effectively to changes in glucose, helping to maintain stable blood sugar levels while minimizing the risk of dangerous drops. This breakthrough could make insulin treatments safer and more effective for people with diabetes.

For more information, visit Nature.